
Five more deaths have been reported to the FDA in patients using intragastric balloon systems, meaning that 12 total deaths …

Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …

Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 …

Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data …

The decision to award the EMA headquarters to Amsterdam was a contentious one, not least because the vote had to …

Amgen and Novartis have announced that their newly FDA-approved treatment for migraines has received a recommendation from the CHMP, generally …

Up until present, no studies had shown that immunotherapies could offer potential treatment for men with prostate cancer; however, at …

The fact that Celgene is currently sailing through choppy waters is no secret to anyone within the industry, it’s facing …

The first day of June – time for another top ten run-down. It’s been a week somewhat characterised by trial …

Israeli biopharmaceutical firm is celebrating the approval in the US of Consensi, a combo of the calcium channel blocker amlodipine …

When rumours first started rumbling about a mega-merger between Bayer and Monsanto, one of the major question marks was on …

Roche has announced that it will no longer seek to develop its treatment for spinal muscular atrophy (SMA), olesoxime, after …

The departure of high-level, big pharma executives to tiny biotechs is steadily becoming a constant stream; the latest is Bill …

Tim de Gavre has been announced as the new chair for the British Generic Manufacturers Association (BGMA), a position he …

The headline figure is that the NHS budget deficit for the year 2017/2018 came in at £960 million, close to …

Pfizer has revealed that its Janus kinase (JAK) inhibitor Xeljanz (tofacitinib) has received FDA approval for the treatment of adult …

Allergan’s share price has been on a steady downward trajectory for the last year and investors are becoming increasingly frustrated …

The new June edition of Pharmafocus is now available to read online.

TherapeuticsMD has succeeded in changing the FDA’s mind on its Imvexxy product, after an initial rejection in May of last …

Mike Elliott, Vice President of Medical Affairs at Gilead (pictured, right), chats about the company’s sponsorship of a ‘A life …